Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Environmental Pollution (Barking, Essex : 1987)
|
December 14, 2004
Screening the wetland plant species Alisma plantago-aquatica, Carex rostrata and Phalaris arundinacea for innate tolerance to zinc and comparison with Eriophorum angustifolium and Festuca rubra Merlin
David J Matthews, Bridget M Moran, Marinus L Otte
Journal of Virology
|
September 21, 2012
Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody
Jane A Potter, Ania M Owsianka, Nathan Jeffery, et al.
Cell Cycle (Georgetown, Tex.)
|
January 25, 2007
Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo
David J Matthews, F Michael Yakes, Jason Chen, et al.
ECS Journal of Solid State Science and Technology : JSS
|
December 4, 2015
Fabrication of a Flexible Amperometric Glucose Sensor Using Additive Processes
Xiaosong Du, Christopher J Durgan, David J Matthews, et al.
Science Immunology
|
June 3, 2022
An innate IL-25-ILC2-MDSC axis creates a cancer-permissive microenvironment for <i>Apc</i> mutation-driven intestinal tumorigenesis
Eric Jou, Noe Rodriguez-Rodriguez, Ana-Carolina F Ferreira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 17, 2008
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation
Torsten Trowe, Sotiria Boukouvala, Keith Calkins, et al.
Oncotarget
|
May 25, 2017
Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
Gordon W Rewcastle, Sharada Kolekar, Christina M Buchanan, et al.
Journal of Molecular Biology
|
March 6, 2013
Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies
Homer Pantua, Jingyu Diao, Mark Ultsch, et al.
Molecular Cancer Therapeutics
|
March 18, 2014
Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway
Peiwen Yu, A Douglas Laird, Xiangnan Du, et al.
Molecular Cancer Therapeutics
|
February 1, 2015
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Paul Foster, Kyoko Yamaguchi, Pin P Hsu, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Environmental Pollution (Barking, Essex : 1987)
|
December 14, 2004
Screening the wetland plant species Alisma plantago-aquatica, Carex rostrata and Phalaris arundinacea for innate tolerance to zinc and comparison with Eriophorum angustifolium and Festuca rubra Merlin
David J Matthews, Bridget M Moran, Marinus L Otte
Journal of Virology
|
September 21, 2012
Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody
Jane A Potter, Ania M Owsianka, Nathan Jeffery, et al.
Cell Cycle (Georgetown, Tex.)
|
January 25, 2007
Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo
David J Matthews, F Michael Yakes, Jason Chen, et al.
ECS Journal of Solid State Science and Technology : JSS
|
December 4, 2015
Fabrication of a Flexible Amperometric Glucose Sensor Using Additive Processes
Xiaosong Du, Christopher J Durgan, David J Matthews, et al.
Science Immunology
|
June 3, 2022
An innate IL-25-ILC2-MDSC axis creates a cancer-permissive microenvironment for <i>Apc</i> mutation-driven intestinal tumorigenesis
Eric Jou, Noe Rodriguez-Rodriguez, Ana-Carolina F Ferreira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 17, 2008
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation
Torsten Trowe, Sotiria Boukouvala, Keith Calkins, et al.
Oncotarget
|
May 25, 2017
Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
Gordon W Rewcastle, Sharada Kolekar, Christina M Buchanan, et al.
Journal of Molecular Biology
|
March 6, 2013
Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies
Homer Pantua, Jingyu Diao, Mark Ultsch, et al.
Molecular Cancer Therapeutics
|
March 18, 2014
Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway
Peiwen Yu, A Douglas Laird, Xiangnan Du, et al.
Molecular Cancer Therapeutics
|
February 1, 2015
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Paul Foster, Kyoko Yamaguchi, Pin P Hsu, et al.
Page
of 2